| --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | Q1 2024 Financial Results & Business Update | | | | | | Nasdaq: OABI | | | | | | May 9, 2024 | | | | | We caution you that this presentation contains forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about the antibody industr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

Exhibit 99.1 OmniAb Reports First Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (May 9, 2024) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. "The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base. We added three new platform licens ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

1 | --- | --- | --- | --- | --- | |-------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q4 and Full Year 2023 Financial Results & Business Update | | | | | | Nasdaq: OABI | | | | | | March 20, 2024 | | | | | Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements rega ...

Matthew Foehr Yes, Joe. Look, I mean, we always -- as you pointed out, we report our numbers net of attrition for active partners, active programs and active clinical and approved products. Largely because we find that gives the best clarity on where the business stands and where it's headed. Attrition, of course, is very natural, very expected in pharmaceutical discovery and development, it can be different stage to stage. And as we're building up our experience with programs and our portfolio, there are s ...

Exhibit 99.1 OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (March 20, 2024) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. "2023 was a year of significant expansion of OmniAb's partnership base and pipeline programs as we continued to execute against our plan, ...

1 Disclaimer All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our technology platform and other technologies, our expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which we operate and ...

Conference Call Participants Matthew Foehr - President and CEO Todd Pettingill - VP, Business Development and Strategy Bill Harriman - SVP, Antibody Discovery Bob Chen - Senior Director, Discovery Systems Doug Krafte - SVP, Ion Channels Kurt Gustafson - CFO OmniAb, Inc. (NASDAQ:OABI) Research & Technology Virtual Event and 3Q23 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Joe Pantginis - H.C. Wainwright & Co. Puneet Souda - Leerink Partners Stephen Willey - Stifel Nishant Gandh ...

For the Transition Period From ______ to ______. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-40720 Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition Report Pursu ...